Toshiyuki Sawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toshiyuki Sawa has a total of 374 co-authors. Here are the top co-authors by number of shared publications:
Takashi Ishiguro
Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Japan
12 shared publicationsTsutomu Yoshida
Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu 500-8323, Japan
12 shared publicationsKazuhiko Nakagawa
Department of Medical Oncology, Faculty of Medicine, Kinki University, Osaka, Japan
11 shared publicationsMasahiro Fukuoka
Department of Medical Oncology Izumi City Hospital Osaka Japan
10 shared publicationsAkane Horiba
Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu 500-8323, Japan
9 shared publicationsKoji Takeda
8 shared publications
Latest Publications
- 27 May 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (7) , 1399-1407
Quantitative evaluation of healthcare information provided to patients with thoracic malignancies: patient satisfaction survey of the Japan Lung Cancer Society
Background Healthcare professionals are increasingly providing medical information to patients. However, few objective evaluations of the information’s usefulness exist. This study aimed to evaluate patient satisfaction with medical information sources, including the JLCS Guidebook and patient advocacy groups, using the European Organization for Research and Treatment of Cancer’s (EORTC) Quality of Life 25-item information module (QLQ-INFO25). Methods Patients with thoracic malignancies were enrolled in the trial in response to calls from patient support groups and the Japanese Lung Cancer Society. Patient satisfaction was based on information obtained from the 2019 Japanese Lung Cancer Society’s patient guidebook and a web-based survey of patients with lung cancer. Satisfaction with the information was analyzed using EORTC QLQ-INFO25 scores and stratified by guidebook use (users vs. non-users). Results Of 332 participants (110 male, 222 female), 283 (85.2%) completed the questionnaire, among which 82 (29.0%) read the guidebook. Participants found the research through online sources or by responding to an invitation from their primary physician or patient support group. Seventy-one users (91%) were satisfied with the guidebook content, as indicated by their individual QLQ–INFO25 scale scores. No statistically significant differences were observed between guidebook users and non-users; however, a trend toward higher satisfaction was noted among participants who used both the guidebook and advocacy groups. Conclusions Our findings suggest that guidebooks and advocacy groups may contribute to improved patient satisfaction; however, further controlled studies are warranted. Our results provide an objective basis for discussing information provision for patients with lung cancer. Strategies should be developed to communicate information reflecting patients’ diverse backgrounds.
- 27 May 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (7) , 1399-1407
Quantitative evaluation of healthcare information provided to patients with thoracic malignancies: patient satisfaction survey of the Japan Lung Cancer Society
Background Healthcare professionals are increasingly providing medical information to patients. However, few objective evaluations of the information’s usefulness exist. This study aimed to evaluate patient satisfaction with medical information sources, including the JLCS Guidebook and patient advocacy groups, using the European Organization for Research and Treatment of Cancer’s (EORTC) Quality of Life 25-item information module (QLQ-INFO25). Methods Patients with thoracic malignancies were enrolled in the trial in response to calls from patient support groups and the Japanese Lung Cancer Society. Patient satisfaction was based on information obtained from the 2019 Japanese Lung Cancer Society’s patient guidebook and a web-based survey of patients with lung cancer. Satisfaction with the information was analyzed using EORTC QLQ-INFO25 scores and stratified by guidebook use (users vs. non-users). Results Of 332 participants (110 male, 222 female), 283 (85.2%) completed the questionnaire, among which 82 (29.0%) read the guidebook. Participants found the research through online sources or by responding to an invitation from their primary physician or patient support group. Seventy-one users (91%) were satisfied with the guidebook content, as indicated by their individual QLQ–INFO25 scale scores. No statistically significant differences were observed between guidebook users and non-users; however, a trend toward higher satisfaction was noted among participants who used both the guidebook and advocacy groups. Conclusions Our findings suggest that guidebooks and advocacy groups may contribute to improved patient satisfaction; however, further controlled studies are warranted. Our results provide an objective basis for discussing information provision for patients with lung cancer. Strategies should be developed to communicate information reflecting patients’ diverse backgrounds.
- Open Access
- 26 October 2025
- Published by Springer Nature in Research Square
Quantitative Evaluation of Healthcare Information Provided to Patients with Lung Cancer: Patient Satisfaction Survey of The Japan Lung Cancer Society
Background: Healthcare professionals are increasingly providing medical information to patients. However, few objective evaluations of the information’s usefulness exist. This study posited that analyzing objective, quantified data facilitates future information provision. Our questionnaire survey on patient satisfaction with medical information using the European Organization for Research and Treatment of Cancer’s (EORTC) Quality of Life 25-item information module (QLQ-INFO25) was unprecedented in Japan. Methods: Lung cancer patients were enrolled in the trial in response to calls from patient support groups and the Japanese Lung Cancer Society. Patient satisfaction was based on information obtained from the 2019 Japanese Lung Cancer Society’s patient guidebook and a web-based survey of patients with lung cancer. Satisfaction with the information was analyzed based on EORTC QLQ-INFO25 scores and stratified into user and nonusers of the guidebook. Results: Of 332 participants (110 male, 222 female), 283 (85.2%) completed the questionnaire, among which, 170 (60.1%) respondents participated in the patient advocacy group and 82 (29.0%) read the guidebook. Participants found the research through online sources or by responding to an invitation from their primary physician or patient support group. Seventy-one users (91%) were satisfied with the guidebook content as shown by the individual scale score on the QLQ–INFO25. No statistically significant differences were observed based on the presence or absence of information in the guidebook. Subgroup analysis revealed a trend toward greater satisfaction among participants that joined the patient group and used the guidebook. Conclusions: Guidebooks and patient advocacy groups are effective in providing information to patients. Our results provide an objective basis for discussing information provision for patients with lung cancer. Strategies should be developed to communicate information reflecting patients’ diverse backgrounds.
- 26 October 2025
- Published by Springer Nature in Research Square
Open AccessQuantitative Evaluation of Healthcare Information Provided to Patients with Lung Cancer: Patient Satisfaction Survey of The Japan Lung Cancer Society
Background: Healthcare professionals are increasingly providing medical information to patients. However, few objective evaluations of the information’s usefulness exist. This study posited that analyzing objective, quantified data facilitates future information provision. Our questionnaire survey on patient satisfaction with medical information using the European Organization for Research and Treatment of Cancer’s (EORTC) Quality of Life 25-item information module (QLQ-INFO25) was unprecedented in Japan. Methods: Lung cancer patients were enrolled in the trial in response to calls from patient support groups and the Japanese Lung Cancer Society. Patient satisfaction was based on information obtained from the 2019 Japanese Lung Cancer Society’s patient guidebook and a web-based survey of patients with lung cancer. Satisfaction with the information was analyzed based on EORTC QLQ-INFO25 scores and stratified into user and nonusers of the guidebook. Results: Of 332 participants (110 male, 222 female), 283 (85.2%) completed the questionnaire, among which, 170 (60.1%) respondents participated in the patient advocacy group and 82 (29.0%) read the guidebook. Participants found the research through online sources or by responding to an invitation from their primary physician or patient support group. Seventy-one users (91%) were satisfied with the guidebook content as shown by the individual scale score on the QLQ–INFO25. No statistically significant differences were observed based on the presence or absence of information in the guidebook. Subgroup analysis revealed a trend toward greater satisfaction among participants that joined the patient group and used the guidebook. Conclusions: Guidebooks and patient advocacy groups are effective in providing information to patients. Our results provide an objective basis for discussing information provision for patients with lung cancer. Strategies should be developed to communicate information reflecting patients’ diverse backgrounds.
- 1 November 2022
- Published by Institute of Electrical Engineers of Japan (IEE Japan) in IEEJ Transactions on Power and Energy
- Vol. 142 (11) , 492
Preface to Special Issue on “New Technologies of Power System Operation based on the Utilization of Meteorological Information”
電力の安定かつ経済的な供給を実現するために,気象情報は電力系統の運用・計画等において積極的に利活用されている。 気象と電力系統の運用は関わりが深いことから,これまでに電気学会技術報告第548号「系統運用と気象情報」(1995
- 1 November 2022
- Published by Institute of Electrical Engineers of Japan (IEE Japan) in IEEJ Transactions on Power and Energy
- Vol. 142 (11) , 492
Preface to Special Issue on “New Technologies of Power System Operation based on the Utilization of Meteorological Information”
電力の安定かつ経済的な供給を実現するために,気象情報は電力系統の運用・計画等において積極的に利活用されている。 気象と電力系統の運用は関わりが深いことから,これまでに電気学会技術報告第548号「系統運用と気象情報」(1995
- 3 August 2020
- Published by ASME International
FEM Stress Analysis and Leakage Behavior of Pipe-Socket Threaded Joints Subjected to Bending Moment and Internal Pressure
This paper is a report of the studies on the mechanical behaviors and leakage characteristics of pipe-socket threaded joints subjected to bending moment as well as internal pressure by means of experimental tests and finite element simulations. The paper dealt with the 3/4″ and 3″ joints, and the joints for both sizes have two different combinations of thread types in the pipe and socket, i.e. taper-taper thread combination or taper-parallel one, respectively. Experimental bending leak tests showed that the taper-taper joints could retain internal pressure under bending load up to nearly plastic collapse. The taper-parallel joints, however, could hardly keep internal pressure against bending moment even the sealing tape was applied to enhance the sealing performance. Finite element analysis was carried out to simulate those bending tests, especially to clarify the deformation and the stress distribution in the engaged threads in detail. The analysis demonstrated that the sealing performance of the joints highly depend on the contact conditions not only at the thread crest to thread root but also in between flank surfaces. A complicated leak path across the engaged threads under bending moment was identified by the simulation.
- 3 August 2020
- Published by ASME International
FEM Stress Analysis and Leakage Behavior of Pipe-Socket Threaded Joints Subjected to Bending Moment and Internal Pressure
This paper is a report of the studies on the mechanical behaviors and leakage characteristics of pipe-socket threaded joints subjected to bending moment as well as internal pressure by means of experimental tests and finite element simulations. The paper dealt with the 3/4″ and 3″ joints, and the joints for both sizes have two different combinations of thread types in the pipe and socket, i.e. taper-taper thread combination or taper-parallel one, respectively. Experimental bending leak tests showed that the taper-taper joints could retain internal pressure under bending load up to nearly plastic collapse. The taper-parallel joints, however, could hardly keep internal pressure against bending moment even the sealing tape was applied to enhance the sealing performance. Finite element analysis was carried out to simulate those bending tests, especially to clarify the deformation and the stress distribution in the engaged threads in detail. The analysis demonstrated that the sealing performance of the joints highly depend on the contact conditions not only at the thread crest to thread root but also in between flank surfaces. A complicated leak path across the engaged threads under bending moment was identified by the simulation.
- Open Access
Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial
BACKGROUND: Bevacizumab combined with platinum‐based chemotherapy has been established as a standard treatment option in the first‐line setting for advanced nonsquamous non–small cell lung cancer (NSCLC). However, there has been no evidence to support the use of bevacizumab beyond disease progression in such patients.METHODS: West Japan Oncology Group 5910L was designed as a multicenter, open‐label, randomized, phase 2 trial of docetaxel versus docetaxel plus bevacizumab every 3 weeks for patients with recurrent or metastatic nonsquamous NSCLC whose disease had progressed after first‐line treatment with bevacizumab plus a platinum‐based doublet. The primary endpoint was progression‐free survival (PFS).RESULTS: One hundred patients were randomly assigned to receive docetaxel (n = 50) or docetaxel plus bevacizumab (n = 50), and this yielded median PFS times of 3.4 and 4.4 months, respectively, with a hazard ratio (HR) of 0.71 and a stratified log‐rank P value of .058, which met the predefined criterion for statistical significance (P < .2). The median overall survival also tended to be longer in the docetaxel plus bevacizumab group (13.1 months; 95% confidence interval [CI], 10.6‐21.4 months) versus the docetaxel group (11.0 months; 95% CI, 7.6‐16.1 months) with an HR of 0.74 (95% CI, 0.46‐1.19; stratified log‐rank P = .11). No unexpected or severe adverse events were recorded.CONCLUSIONS: Further evaluation of bevacizumab beyond disease progression is warranted for patients with advanced NSCLC whose disease has progressed after treatment with bevacizumab plus a platinum‐based doublet. Cancer 2016;122:1050–1059. © 2016 American Cancer Society
Open AccessBevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial
BACKGROUND: Bevacizumab combined with platinum‐based chemotherapy has been established as a standard treatment option in the first‐line setting for advanced nonsquamous non–small cell lung cancer (NSCLC). However, there has been no evidence to support the use of bevacizumab beyond disease progression in such patients.METHODS: West Japan Oncology Group 5910L was designed as a multicenter, open‐label, randomized, phase 2 trial of docetaxel versus docetaxel plus bevacizumab every 3 weeks for patients with recurrent or metastatic nonsquamous NSCLC whose disease had progressed after first‐line treatment with bevacizumab plus a platinum‐based doublet. The primary endpoint was progression‐free survival (PFS).RESULTS: One hundred patients were randomly assigned to receive docetaxel (n = 50) or docetaxel plus bevacizumab (n = 50), and this yielded median PFS times of 3.4 and 4.4 months, respectively, with a hazard ratio (HR) of 0.71 and a stratified log‐rank P value of .058, which met the predefined criterion for statistical significance (P < .2). The median overall survival also tended to be longer in the docetaxel plus bevacizumab group (13.1 months; 95% confidence interval [CI], 10.6‐21.4 months) versus the docetaxel group (11.0 months; 95% CI, 7.6‐16.1 months) with an HR of 0.74 (95% CI, 0.46‐1.19; stratified log‐rank P = .11). No unexpected or severe adverse events were recorded.CONCLUSIONS: Further evaluation of bevacizumab beyond disease progression is warranted for patients with advanced NSCLC whose disease has progressed after treatment with bevacizumab plus a platinum‐based doublet. Cancer 2016;122:1050–1059. © 2016 American Cancer Society
- Open Access
- 5 October 2015
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 57 (1) , 50-54
A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non–small-cell lung cancer
We investigated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) with concurrent radiotherapy for unresectable locally advanced non–small-cell lung cancer (NSCLC). Patients with Stage III NSCLC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Concurrent chemoradiotherapy consisted of weekly administration of nab-PTX (40 mg/m 2 ) plus CBDCA (area under the plasma concentration time curve (AUC) 2) and thoracic radiotherapy (60 Gy/30 fractions) for a total of 6 weeks. After concurrent chemoradiotherapy, patients received an additional two cycles of consolidation phase chemotherapy that consisted of 4-week cycles of nab-PTX (100 mg/m 2 on Days 1, 8 and 15)/CBDCA (AUC 5 mg/ml/min on Day 1). Response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors. Progression-free survival and overall survival were estimated using the Kaplan–Meier method. Toxicity was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events. A total of 10 patients were enrolled in this trial between September 2013 and January 2014 from three institutes. The overall response rate was 40.0% and the median progression-free survival was 6.7 months. Treatment-related death occurred in two patients. Grade 2 or worse severe radiation pneumonitis was observed in all three patients that had the volume of lung receiving at least 20 Gy (V20) >30%. The results of this study indicate that no further investigation is warranted into nab-PTX and CBDCA with concurrent thoracic radiation for Stage III NSCLC with V20 > 30% due to severe toxicity.
- 5 October 2015
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 57 (1) , 50-54
Open AccessA phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non–small-cell lung cancer
We investigated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) with concurrent radiotherapy for unresectable locally advanced non–small-cell lung cancer (NSCLC). Patients with Stage III NSCLC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Concurrent chemoradiotherapy consisted of weekly administration of nab-PTX (40 mg/m 2 ) plus CBDCA (area under the plasma concentration time curve (AUC) 2) and thoracic radiotherapy (60 Gy/30 fractions) for a total of 6 weeks. After concurrent chemoradiotherapy, patients received an additional two cycles of consolidation phase chemotherapy that consisted of 4-week cycles of nab-PTX (100 mg/m 2 on Days 1, 8 and 15)/CBDCA (AUC 5 mg/ml/min on Day 1). Response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors. Progression-free survival and overall survival were estimated using the Kaplan–Meier method. Toxicity was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events. A total of 10 patients were enrolled in this trial between September 2013 and January 2014 from three institutes. The overall response rate was 40.0% and the median progression-free survival was 6.7 months. Treatment-related death occurred in two patients. Grade 2 or worse severe radiation pneumonitis was observed in all three patients that had the volume of lung receiving at least 20 Gy (V20) >30%. The results of this study indicate that no further investigation is warranted into nab-PTX and CBDCA with concurrent thoracic radiation for Stage III NSCLC with V20 > 30% due to severe toxicity.
- 20 February 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (6) , 575-581
Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L
Purpose: This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods: Chemotherapy-naïve patients with stage III, stage IV, or recurrent NSCLC age ≥ 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m2 on day 1, every 3 weeks, or docetaxel 20 mg/m2 plus cisplatin 25 mg/m2 on days 1, 8, and 15, every 4 weeks. The primary end point was overall survival (OS). Results: In the first interim analysis, OS of the doublet arm was inferior to that of the monotherapy arm (hazard ratio [HR], 1.56; 95% CI, 0.98 to 2.49), and the predictive probability that the doublet arm would be statistically superior to the monotherapy arm on final analysis was 0.996%, which led to early study termination. In total, 276 patients with a median age of 76 years (range, 70 to 87 years) were enrolled. At the updated analysis, the median survival time was 14.8 months for the monotherapy arm and 13.3 months for the doublet arm (HR, 1.18; 95% CI, 0.83 to 1.69). The rates of grade ≥ 3 neutropenia and febrile neutropenia were higher in the monotherapy arm, and those of anorexia and hyponatremia were higher in the doublet arm. Conclusion: This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients.
- 20 February 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (6) , 575-581
Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L
Purpose: This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods: Chemotherapy-naïve patients with stage III, stage IV, or recurrent NSCLC age ≥ 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m2 on day 1, every 3 weeks, or docetaxel 20 mg/m2 plus cisplatin 25 mg/m2 on days 1, 8, and 15, every 4 weeks. The primary end point was overall survival (OS). Results: In the first interim analysis, OS of the doublet arm was inferior to that of the monotherapy arm (hazard ratio [HR], 1.56; 95% CI, 0.98 to 2.49), and the predictive probability that the doublet arm would be statistically superior to the monotherapy arm on final analysis was 0.996%, which led to early study termination. In total, 276 patients with a median age of 76 years (range, 70 to 87 years) were enrolled. At the updated analysis, the median survival time was 14.8 months for the monotherapy arm and 13.3 months for the doublet arm (HR, 1.18; 95% CI, 0.83 to 1.69). The rates of grade ≥ 3 neutropenia and febrile neutropenia were higher in the monotherapy arm, and those of anorexia and hyponatremia were higher in the doublet arm. Conclusion: This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients.
- 1 January 2015
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 54 (16) , 1977-1980
Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2015
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 54 (16) , 1977-1980
Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 November 2014
- Vol. 41 (12) , 2044-6
[Improvement in quality of life by endobronchial electrocautery using snare in a patient with advanced non-small cell lung cancer].
Endobronchial electrocautery using a polypectomy snare may serve as a useful tool for treating patients with airway obstructing polypoid tumors. An 84-year-old man was admitted to our hospital because of an abnormal shadow observed on chest radiography. He was diagnosed with advanced squamous cell carcinoma, located in the right lower lobe of the lung along with metastatic lesions and obstructive pneumonia. He declined systemic chemotherapy because of his age. Endobronchial electrocautery using a polypectomy snare was performed to treat the obstructive pneumonia. The patient's quality of life improved after polypectomy. This was due to an improvement in malaise and a spontaneous decrease in the size of the hepatic metastasis tumor.
- 1 November 2014
- Vol. 41 (12) , 2044-6
[Improvement in quality of life by endobronchial electrocautery using snare in a patient with advanced non-small cell lung cancer].
Endobronchial electrocautery using a polypectomy snare may serve as a useful tool for treating patients with airway obstructing polypoid tumors. An 84-year-old man was admitted to our hospital because of an abnormal shadow observed on chest radiography. He was diagnosed with advanced squamous cell carcinoma, located in the right lower lobe of the lung along with metastatic lesions and obstructive pneumonia. He declined systemic chemotherapy because of his age. Endobronchial electrocautery using a polypectomy snare was performed to treat the obstructive pneumonia. The patient's quality of life improved after polypectomy. This was due to an improvement in malaise and a spontaneous decrease in the size of the hepatic metastasis tumor.
- 1 October 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v72
International Survey for Smoking Prevalence and Spontaneous Awareness of the Symptmos of Lung Cancer
Purpose: This survey seeks to understand the smoking prevalence and spontaneous awareness of the signs and symptom across 21 countries by Global Lung Cancer Coalition. Method: National representative quota sample of respondents was interviewed between June and August 2013. The same two questions were asked of respondents to enable comparisons to be drawn. Results: Approaching one in four Japanese respondents are current smokers (24%). The gap in prevalence between men and women is particularly large in Japan as 38% of men say they are a current smoker compared to 10 % of women. General or unspecified coughing is comfortably the symptoms of lung cancer. Japanese people are most aware of (50%), and there is a 28 percentage point gap to the next most frequently recognized symptom (breathlessness, 22%), with a cough that does not go away closely following (21%). Conclusion: The varying degree of awareness of the symptoms shows that it will be difficult to raise awareness of them all. Instead it may be more effective to focus the commonly recognized symptoms in each country.
- 1 October 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v72
International Survey for Smoking Prevalence and Spontaneous Awareness of the Symptmos of Lung Cancer
Purpose: This survey seeks to understand the smoking prevalence and spontaneous awareness of the signs and symptom across 21 countries by Global Lung Cancer Coalition. Method: National representative quota sample of respondents was interviewed between June and August 2013. The same two questions were asked of respondents to enable comparisons to be drawn. Results: Approaching one in four Japanese respondents are current smokers (24%). The gap in prevalence between men and women is particularly large in Japan as 38% of men say they are a current smoker compared to 10 % of women. General or unspecified coughing is comfortably the symptoms of lung cancer. Japanese people are most aware of (50%), and there is a 28 percentage point gap to the next most frequently recognized symptom (breathlessness, 22%), with a cough that does not go away closely following (21%). Conclusion: The varying degree of awareness of the symptoms shows that it will be difficult to raise awareness of them all. Instead it may be more effective to focus the commonly recognized symptoms in each country.